Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu

Abstract

Abstract: Objective To compare the therapeutic effects of biochemotherapy regimen with Herceptin plus taxol (TAX) and the chemotherapy regimen with epirubicin plus TAX against Her-2/neu-positive breast cancer and observe the changes in serum tumor markers in patients receiving biochemotherapy. Methods Seventy-three patients with advanced breast cancer positive for Her-2/neu as revealed by immunohistochemistry were divided into the study group (n=32) to receive treatment with the regimen of Herceptin plus TAX and control group (n=41) with the regimen of epirubicin(EPI) plus TAX. The therapeutic effects of the regimens were observed and in the study group, the relationship of the therapeutic effect with Her-2/neu positivity and changes in serum tumor markers were examined. Results The objective response rate and clinical benefit response rate were obviously higher in the study group than in the control group. In the study group, the clinical response rate of patients with positive immunostaining for Her-2/neu of grades 1+, 2+ and 3+ were 0%, 44.4% and 63.6%, respectively, as compared with those in the control group of 8.3%, 36.4%, and 38.9%, respectively, and the treatment resulted in lowered levels of serum tumor markers without significant changes in CA153, tps and CEA (P<0.05) after treatment, but CA125 showed no significant difference (P>0.05). Conclusions In patients with advanced breast cancer with positive immunostaining for Her-2/neu of grade 3+, the regimen of Herceptin plus TAX can be more effective than the chemotherapeutic regimen of EPI plus TAX. Patients with Her-2/neu (+++) benefit more from the treatment than those with Her-2/neu (++). Serum CEA, CA153 and TPS levels also possess some value in evaluating the therapeutic effects of the regimens.

CLC Number:

CUI Fei, LUO Rong-cheng, CHEN Jin-zhang, CHEN Bin, HUANG Yu-xian. Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu[J]. Journal of Southern Medical University, 2005, 25(12): 1533-1536.

References

[1] 周爱萍.乳腺癌靶向治疗:Herceptin的研究进展[J].国外医学·肿瘤学分册,2000,8(4):167-70.
[2] Baselga J,Tripathy D,Mendelsohn J,et al.Phase Ⅱ study of weekly intravenous trastuzumab (Herceptin) in patients with HER-2/neu overexpressing metastatic breast cancer[J].J Clin Oncol,1996,14(3):737-44.
[3] Vogel CL,Cobleigh MA,Tripathy D,et al.First-line Herceptin mo notherapy in metastatic breast cancer [J].Oncology,2001,61 (Suppl2):37-42.
[4] 宋海珠,罗荣城.Herceptin治疗转移性乳腺癌的研究进展[J].中国肿瘤生物治疗杂志,2002,9(2):144-5.Song HZ,Luo RC.Progress of the therapy of matestatic breast cancer ofherceptin[J].Chin J Cancer Biother,2002,9(2):144-5.
[5] Fornier M,Esteva FJ,Seidman AD.Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer [J].Semin Oncol,2000,27(6 Suppl 11):38-45.
[6] 孙燕,周际昌.临床肿瘤内科手册[M].第4版,北京:人民卫生出版社,2003.107-13.
[7] Hayes DF,Thor AD.c-erbB-2 in breast cancer:Development of a clinically useful marker[J].Semin Oncol,2002,29(3):231-45.
[8] Aziz A,Pervez S,Khan S,et al.Significance ofimmunohistohemical c-erbB-2 product localization pattern for prognosis in human breast cancer[J].Pathol Oncol Res,2001,7(3):190-6.
[9] Baselga J,Norton L,Albanell J,et al.Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts[J].Cancer Res,1998,58(13):2825-31.
[10] Senapad S,Neungton S,Thirapakawong C,et al.Predictive value of the combined serum CA125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer [J].Anticancer Res,2000,20(2B):1297-300.
[11] 汤沼猷.现代肿瘤学[M].上海医科大学出版社,1993.3549.
[12] Berruti A,Tampellini M,Torta M,et al.Prognostic value in predicting overall survival of two mucinus markers:CA15-3 and CA125in breast cancer patients at first relapse of disease [J].Eur J Cancer,1994,30A(14):2082-4.
[13] Krammer S,RaffU,Jager W,et al.CA125 as an indicator ofpleural metastases in breast cancer[J].Anticancer Res,1996,16(5B):3165-8.
[14] Arjun MD,Thomas MD,Steven PD.Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women[J].Cancer,1999,85(9):2068-72.

[1]	LI Xin-an,AN Jing Department of Embryology and Histology,Southern Medical University,Guangzhou 510515,China. Mechanisms of the expression of exogenous genes injected via the mammary duct in rat mammary gland tissue [J]. Journal of Southern Medical University, 2006, 26(12): 1774-.
[2]	WU Wu-jun1,ZENG Jian2,PAN Cheng-en1 1Department of General Surgery,First Hospital of Xi’an Jiaotong University,Xi’an 710061,China;2Department of Gastrointestinal and Glands Surgery,First Affiliated Hospital,Guangxi Medical University,Nanning 530021,China. Efficacy of activated charcoal-epirubicin suspension for treatment of breast cancer with axillary metastasis [J]. Journal of Southern Medical University, 2006, 26(12): 1812-1814.
[3]	KANG Hua-feng,WANG Xi-jing,LIU Xiao-xu,DAI Zhi-jun,XUE Feng-jie,XUE Xing-huan Department of Oncological Surgery,Second Affiliated Hospital,School of Medicine,Xi’an Jiaotong University,Xi’an 710004,China. Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism [J]. Journal of Southern Medical University, 2006, 26(11): 1599-1602.
[4]	LI Gui-ping1, ZHANG Yi-fan2, WANG Yong-xian3 1Departmant of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; 2Department of Nuclear Medicine, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China; 3Radiopharmaceutical Research Center, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China. 188Re-labeled herceptin inhibits proliferation of breast cancer cell line SKBR-3 in vitro [J]. Journal of Southern Medical University, 2006, 26(10): 1455-1457.
[5]	. [J]. Journal of Southern Medical University, 2006, 26(09): 1378-1379.
[6]	WANG Xiao-yu1, LIN Shao-qiang2, LI Jun-wu2, Kemmner Wolfgang3, DING Yan-qing4 Department of Obstetrics and Gynecology, First Affiliated Hospital of Ji’nan University1, Department of Microbiology and Immunology of Medical College2, Jinan University, Guangzhou 510630, China; 3Max-Delbrueck Center for Molecular Medicine,Berlin 13125, Germany; 4Institute of Oncology, Southern Medical University, Guangzhou 510515, China. Effect of cell surface sialic acid and their linkages on adhesion of mammary carcinoma cells [J]. Journal of Southern Medical University, 2006, 26(06): 742-746.
[7]	WANG Xiao-bing, YANG Qing-xu, PEI Xiao-juan Department of Pathology, Huizhou Central Hospital, Huizhou 516001, China. Expression of angiogenesis-related factors in invasive breast cancer and its clinical significance [J]. Journal of Southern Medical University, 2006, 26(06): 860-863.
[8]	HU Xiao-qu1,QIN Li1,SU Feng-xi1,YAO He-rui2,CHEN Ji-sheng1,GONG Chang1,GUO Ju-jiang1,YU Feng-yan1,JIA Hai-xia1 1Center of Breast Cancer,2Department of Oncology,Second Hospital of Sun Yat-sen University,Guangzhou 510272,China. Vector-mediated HER-2 RNA interference against HER-2-positive breast cancer [J]. Journal of Southern Medical University, 2006, 26(05): 570-572.
[9]	ZHANG Shu-qun1,ZHANG Shu-hui2,XUE Xin-huan1,WANG Xi-jing1,JIANG Jian-tao1 1Department of Oncology,Second Hospital,Xi’an Jiaotong University,Xi’an 710004,China;2Department of Chemical Engineering,Northwestern Polytechnical University,Xi’an 710072,China. Synergism between a siRNA targeted to survivin and 5-FU in inhibiting MCF-7 cell proliferation in vitro [J]. Journal of Southern Medical University, 2006, 26(03): 251-254.
[10]	FAN Yi-xiang,LUO Rong-Cheng,FANG Yong-Xin,YAN Xiao,Department of Oncology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China. Preparation,quality control and biodistribution of 131I-herceptin in New Zealand rabbits [J]. Journal of Southern Medical University, 2006, 26(03): 361-.
[11]	XU Lei, BAI Zhong-hong, XU Ruan-cheng, YAN Hui, WANG Fang-ju, LUO Rong-cheng Department of Oncology, 91 Hospital of PLA, Jiaozuo 454003, China;Oncology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Expressions of Her-2, EGFR, PS-2 and ER in breast cancer and their clinical implications [J]. Journal of Southern Medical University, 2006, 26(02): 231-233.
[12]	TAN Ke, FAN Yi-xiang, MIAO Jing-xia, L(?) Cheng-wei, YAN Xiao, LUO Rong-cheng Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Killing effect of sequential Herceptin and adriamycin treatment on breast cancer cell line in vitro [J]. Journal of Southern Medical University, 2006, 26(02): 234-236.
[13]	LI Rong, ZHENG Hang, LUO Rong-cheng. Cloning and expression of the HER2 gene in MCF-7 cells [J]. Journal of Southern Medical University, 2005, 25(10): 1264-1267.
[14]	ZHENG Hang, LUO Rong-cheng. Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer [J]. Journal of Southern Medical University, 2005, 25(10): 1293-1294,1298.
[15]	WU Wu-jun¹, PAN Cheng-en¹, ZENG jian². Effect of preoperative lymphatic chemotherapy on Bcl-2 and Bax expression in axillary metastasis of breast cancer [J]. Journal of Southern Medical University, 2005, 25(08): 1001-1004.